Across TCGA pan-cancer cohorts, TRAJ12 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAJ12 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher TRAJ12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ12 expression acts as an unfavorable survival marker.

PRAD and SKCM are the cancer types where TRAJ12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.224	0.775	.033	4	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAJ12 tumor-vs-normal RNA expression · all TRAJ12 data types